



## TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting

**San Diego, CA – March 27, 2017** – TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that TRC694 preclinical data will be presented at the upcoming American Association for Cancer Research (AACR) annual meeting to be held April 1-5, 2017, in Washington, D.C.

Lut Janssen and colleagues from Janssen Research & Development will present a poster featuring data from preclinical studies of TRC694. The presentation details are as follows:

**Abstract Number:** 4199  
**Abstract Title:** Inhibition of NF-kB inducing kinase (NIK) selectively abrogates NIK and TRAF3 mutant multiple myeloma tumor growth  
**Session Category:** Experimental and Molecular Therapeutics  
**Location:** Section 7, Poster Board Number 22  
**Date:** Tuesday, April 4, 2017  
**Time:** 1:00pm – 5:00pm EDT

The poster will be available on the Company's website.

### About TRC694

TRC694 is a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase (NIK) with the potential to be first-in-class that was discovered by Janssen and licensed by TRACON in September 2016. In pre-clinical studies, TRC694 selectively repressed P52/RelB mediated non-canonical NF-kB gene expression and inhibited NIK and TRAF3 mutant cell line proliferation *in vitro* and tumor growth *in vivo*. Genetic alterations leading to stabilization of NIK are found in a subset of B-cell malignancies: multiple myeloma, mantle-cell lymphoma (where it is associated with ibrutinib resistance), diffuse large B-cell lymphoma, Hodgkin's lymphoma, and chronic lymphocytic leukemia.

### About TRACON

TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company's clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at [www.traconpharma.com](http://www.traconpharma.com).



Company Contact:

Casey Logan

Chief Business Officer

(858) 550-0780 ext. 236

[clogan@traconpharma.com](mailto:clogan@traconpharma.com)

Investor Contact:

Andrew McDonald

LifeSci Advisors LLC

646-597-6987

[Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)